ORGN:NASDAQOrigin Materials, Inc. Analysis
Data as of 2026-05-19 - not real-time
$1.53
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Origin Materials is trading well below its long‑term average, with the 20‑day SMA (≈$1.87) already under the 50‑day SMA (≈$2.47) and dramatically distant from the 200‑day SMA (≈$10.33), signaling a prolonged downtrend. The RSI sits at 38, indicating modest oversold pressure but not yet a clear reversal, while the MACD histogram turned marginally positive, offering only a faint bullish hint that has not overcome the overall bearish trend direction. Volatility is extreme at over 195% on a 30‑day basis and beta exceeds 1.6, exposing the stock to outsized market swings, compounded by a historic max drawdown of roughly 95%. Fundamental metrics are equally distressing: negative earnings, a trailing PE of zero, a P/B of 0.08 and a price‑to‑sales under 1, yet operating cash flow and free cash flow are deeply negative, and the balance sheet shows a debt‑to‑equity ratio near 26%. The latest material news confirms that the board has approved a technology sale and an orderly wind‑down, positioning liquidation as the preferred route to preserve any residual shareholder value. With market cap under $9 million, thin liquidity and a support level just above $1.22, any upside is tightly constrained.
Given these dynamics, the stock’s price action is dominated by technical weakness, severe financial strain, and a definitive strategic pivot toward dissolution. The convergence of a bearish technical setup, extreme price volatility, and a corporate plan to liquidate assets suggests that the remaining upside is limited to the modest premium that a liquidation may deliver over current levels. Investors should therefore treat ORGN as a high‑risk, value‑oriented play with minimal upside potential and consider exiting positions promptly.
Given these dynamics, the stock’s price action is dominated by technical weakness, severe financial strain, and a definitive strategic pivot toward dissolution. The convergence of a bearish technical setup, extreme price volatility, and a corporate plan to liquidate assets suggests that the remaining upside is limited to the modest premium that a liquidation may deliver over current levels. Investors should therefore treat ORGN as a high‑risk, value‑oriented play with minimal upside potential and consider exiting positions promptly.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 9/10
Key Factors
- Board‑approved liquidation and technology sale
- Bearish technical indicators (price below SMA20/50, bearish trend)
- Extreme volatility and high beta
Medium Term
1–3 yearsCautious
Model confidence: 8/10
Key Factors
- Continued negative cash flows and operating losses
- Low market capitalization and thin trading volume
- Potential further price erosion as wind‑down proceeds are realized
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Fundamental insolvency risk and high max drawdown
- Absence of dividend or earnings recovery prospects
- Structural sector challenges for small‑cap chemical firms
Key Metrics & Analysis
Financial Health
Revenue Growth-91.20%
P/E Ratio-4.4
ROE-119.58%
ROA-16.52%
Debt/Equity25.87
P/B Ratio0.1
Op. Cash Flow$-29221000
Free Cash Flow$-36314752
Technical Analysis
TrendBearish
RSI38.6
Support$1.22
Resistance$2.66
MA 20$1.87
MA 50$2.47
MA 200$10.33
MACDBullish
VolumeIncreasing
Fear & Greed Index89.25
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta1.65
Volatility195.27%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.